Literature DB >> 9119398

Alternative promoters of gene MAGE4a.

E De Plaen1, B Naerhuyzen, C De Smet, J P Szikora, T Boon.   

Abstract

Gene MAGE-4 (HGMW-approved symbol MAGE4) is expressed in several types of tumors, but not in normal tissues, except testis and placenta. The 5' end of this gene contains eight homologous exons spread over a 5.8-kb region. These exons are alternatively spliced to a unique second exon and a unique third exon, which encodes a protein of 317 amino acids. The analysis of transcripts found in testis, placenta, and a sarcoma cell line showed that each of the alternative first exons is used in at least one of these tissues. Various regions of the promoter of the fifth alternative exon (1.5) were cloned in a luciferase reporter plasmid, and the constructs were transfected in a sarcoma cell line that expresses MAGE-4. Two Ets motifs located between positions -70 and -29 relative to the transcription start site were found to drive 55% of the promoter activity. A region containing a Sp1 consensus binding site located upstream of the two Ets motifs was found to be responsible for 44% of the transcriptional activity. MAGE-4a promoters 1.4 and 1.6, which also contain the Sp1 and the two Ets binding motifs, supported a level of transcription comparable to that of promoter 1.5, whereas promoter 1.1, which contains only one Ets binding site, was sixfold less active. In line with observations made with gene MAGE-1 (HGMW-approved symbol MAGE1), we found that promoter 1.5 stimulated a high level of transcription in a melanoma cell line that does not express MAGE-4. This suggests that the tumor-specific expression of MAGE genes is not determined by the presence of specific transcription factors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9119398     DOI: 10.1006/geno.1996.4566

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  6 in total

1.  DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11.

Authors:  Smitha R James; Carlos D Cedeno; Ashok Sharma; Wa Zhang; James L Mohler; Kunle Odunsi; Elizabeth M Wilson; Adam R Karpf
Journal:  Epigenetics       Date:  2013-07-09       Impact factor: 4.528

2.  HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance.

Authors:  P Paul; N Rouas-Freiss; I Khalil-Daher; P Moreau; B Riteau; F A Le Gal; M F Avril; J Dausset; J G Guillet; E D Carosella
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

3.  Evolution of the exon-intron structure and alternative splicing of the MAGE-A family of cancer/testis antigens.

Authors:  Irena I Artamonova; Mikhail S Gelfand
Journal:  J Mol Evol       Date:  2004-11       Impact factor: 2.395

4.  Epigenetic modulation of cancer-germline antigen gene expression in tumorigenic human mesenchymal stem cells: implications for cancer therapy.

Authors:  Morten Gjerstorff; Jorge S Burns; Ole Nielsen; Moustapha Kassem; Henrik Ditzel
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

5.  Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer.

Authors:  Viswanath Gunda; Alexandria P Cogdill; Maria J Bernasconi; Jennifer A Wargo; Sareh Parangi
Journal:  Surgery       Date:  2013-12       Impact factor: 3.982

6.  Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene-A4 nanogel.

Authors:  Noriaki Kyogoku; Hiroaki Ikeda; Takahiro Tsuchikawa; Takehiro Abiko; Aki Fujiwara; Takehiro Maki; Yoshiyuki Yamamura; Masaomi Ichinokawa; Kimitaka Tanaka; Naoko Imai; Yoshihiro Miyahara; Shinichi Kageyama; Hiroshi Shiku; Satoshi Hirano
Journal:  Oncol Lett       Date:  2016-10-13       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.